NCT02463994

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking the cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of the cancer by the body's immune cells in the presence of MPDL3280A.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	MPDL3280A	Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
RADIATION	Hypofractionated Radiotherapy	Hypofractionated Image-Guided Radiotherapy (HIGRT)

Timeline

• Start date: 2015-10-01
• Primary completion: 2018-11-07
• Completion: 2018-11-07
• First posted: 2015-06-08
• Last updated: 2019-02-08

Locations

2 sites across 1 country: United States